Innovative Strategies for Ovarian Aging: The Role of Gut Microbiota

As societal and economic development progresses, women are increasingly postponing their first pregnancies due to career demands, confronting significant reproductive challenges and declining fertility as they age. Ovarian aging, characterized by a decline in both the quality and quantity of ovarian follicles, is one of the earliest manifestations of natural female aging and plays a pivotal role in reproductive decline [1]. Unlike males, females have a finite reproductive lifespan, determined early in life by the number of viable oocytes. Ovarian aging, one of the earliest signs of natural female aging, plays a critical role in reproductive decline, as it regulates the depletion of resting follicles and the quality of oocytes. The factors influencing ovarian aging are multifaceted, involving DNA instability, telomere attrition, epigenetic changes, mitochondrial dysfunction and gut microbiota disturbances [2-13]. Recent research highlights the gut microbiota's active role in the aging process, influencing overall health and fitness [14,15]. Notably, fecal microbiota transplantation has been shown to improve ovarian function in aged mice, and differences in gut microbiota composition have been observed in women with premature ovarian insufficiency. These findings suggest that targeting gut microbiota could be a promising strategy to combat ovarian aging and improve female reproductive health.

Gut microbiota, often referred to as the “second genome” significantly influences various physiological processes, including those related to ovarian function [16]. The gut microbiota affects follicular development, oocyte maturation, and ovulation, all of which are critical for maintaining reproductive health. Studies have shown that alterations in gut microbiota composition can impact these processes, suggesting a regulatory role of gut microbiota in ovarian aging.

The interaction between gut microbiota and ovarian function is complex and multifaceted. Gut microbiota can influence ovarian function through metabolic and secretory pathways, impacting hormone levels, immune responses, and inflammatory processes. For instance, certain gut bacteria produce Short-Chain Fatty Acids (SCFAs) that play a role in regulating hormone levels and reducing inflammation, thereby supporting ovarian health [17]. Moreover, gut microbiota can influence the production of essential vitamins and nutrients, such as B vitamins and folate, which are crucial for reproductive health. 

The immune-modulatory effects of gut microbiota also play a significant role in ovarian aging. By modulating the immune response, gut microbiota can help maintain a balanced inflammatory state, which is essential for healthy ovarian function [18]. Chronic inflammation is a known contributor to aging and age-related diseases, including ovarian aging. Therefore, maintaining a healthy gut microbiota can potentially mitigate chronic inflammation and support ovarian health.

(1) Fecal Microbiota Transplantation (FMT): FMT involves transferring gut microbiota from healthy donors to patients to restore a healthy microbiota composition. Studies have shown that FMT from young to aged mice can improve ovarian function and delay ovarian aging, suggesting its potential as a therapeutic strategy [14]. However, the application of FMT in humans requires careful consideration of safety, donor selection and ethical concerns. 

(2) Probiotic therapy: Probiotics are live microorganisms that provide health benefits when administered in adequate amounts. Probiotic supplementation has shown promise in improving ovarian function and delaying ovarian aging by modulating gut microbiota composition and activity. Specific strains of probiotics, such as Lactobacillus and Bifidobacterium, have been identified for their potential benefits in reproductive health [19,20]. These probiotics can enhance gut barrier function, reduce inflammation, and promote the production of beneficial metabolites. 

(3) Prebiotics and dietary interventions: Prebiotics are non-digestible food ingredients that promote the growth of beneficial gut bacteria. Incorporating prebiotics into the diet, along with a balanced intake of fibers, vitamins, and minerals, can support a healthy gut microbiota. Dietary interventions that include fermented foods, whole grains, and fruits and vegetables can also positively influence gut microbiota composition and function [21]. 

(4) Pharmacological approaches: Emerging research is exploring the use of pharmacological agents to modulate gut microbiota. These agents can selectively target harmful bacteria or enhance the growth of beneficial ones. While still in the experimental stage, pharmacological modulation of gut microbiota holds promise for future therapeutic applications in preventing and alleviating ovarian aging. 

(5) Challenges and Future Directions: While the potential of gut microbiota modulation in preventing and alleviating ovarian aging is promising, further research is needed to understand the underlying mechanisms and establish effective therapeutic protocols. Clinical trials and longitudinal studies will be crucial in translating these findings into practical applications for human health. Additionally, personalized approaches that consider individual variations in gut microbiota composition and genetic background may enhance the effectiveness of these interventions. Ethical and regulatory considerations are also paramount in advancing gut microbiota-based therapies. Ensuring the safety and efficacy of these treatments, along with addressing potential risks and ethical concerns, will be essential for their successful implementation in clinical practice.

The modulation of gut microbiota presents a novel and promising strategy for the prevention and alleviation of ovarian aging. By understanding and harnessing the complex interactions between gut microbiota and ovarian function, we can develop new interventions to support reproductive health and extend ovarian lifespan. This approach not only offers potential benefits for women facing age-related reproductive challenges but also contributes to the broader field of aging research and health promotion.

Not applicable.

Not applicable.

The authors declare no conflict of interest.’

Not applicable.

1. Zhang J, Chen Q, Du D, Wu T, Wen J, et al. (2019) Can ovarian aging be delayed by pharmacological strategies? Aging (Albany NY) 11: 817-832.
2. Rinaldi VD, Bloom JC, Schimenti JC (2020) Oocyte Elimination Through DNA Damage Signaling from CHK1/CHK2 to p53 and p63. Genetics 215: 373-378.
3. Xu X, Chen X, Zhang X, Liu Y, Wang Z, et al. (2017) Impaired telomere length and telomerase activity in peripheral blood leukocytes and granulosa cells in patients with biochemical primary ovarian insufficiency. Hum Reprod 32: 201-207.
4. Butts S, Riethman H, Ratcliffe S, Shaunik A, Coutifaris C, et al. (2009) Correlation of telomere length and telomerase activity with occult ovarian insufficiency. J Clin Endocrinol Metab 94: 4835-4843.
5. Kasapoglu I, Seli E (2020) Mitochondrial Dysfunction and Ovarian Aging. Endocrinology 161: bqaa001.
6. Wang T, Zhang M, Jiang Z, Seli E (2017) Mitochondrial dysfunction and ovarian aging. Am J Reprod Immunol 77.
7. Tesarik J, Galán-Lázaro M, Mendoza-Tesarik R (2021) Ovarian Aging: Molecular Mechanisms and Medical Management. Int J Mol Sci 22: 1371.
8. Ruth KS, Day FR, Hussain J, Martínez-Marchal A, Aiken CE, et al. (2021) Genetic insights into biological mechanisms governing human ovarian ageing. Nature 596: 393-397.
9. Ávila J, González-Fernández R, Rotoli D, Hernández J, Palumbo A (2016) Oxidative Stress in Granulosa-Lutein Cells From In Vitro Fertilization Patients. Reprod Sci 23: 1656-1661.
10. Ahmed TA, Ahmed SM, El-Gammal Z, Shouman S, Ahmed A, et al. (2020) Oocyte Aging: The Role of Cellular and Environmental Factors and Impact on Female Fertility. Adv Exp Med Biol 1247: 109-123.
11. Yang Y, Yang Y, Yang J, Zhao X, Wei X (2020) Tumor Microenvironment in Ovarian Cancer: Function and Therapeutic Strategy. Front Cell Dev Biol 8: 758.
12. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G (2023) Hallmarks of aging: An expanding universe. Cell 186: 243-278.
13. Park SU, Walsh L, Berkowitz KM (2021) Mechanisms of ovarian aging. Reproduction 162: 19-33.
14. Xu L, Zhang Q, Dou X, Wang Y, Wang J, et al. (2022) Fecal microbiota transplantation from young donor mice improves ovarian function in aged mice. J Genet Genomics 49: 1042-1052.
15. Wu J, Zhuo Y, Liu Y, Chen Y, Ning Y, et al. (2021) Association between premature ovarian insufficiency and gut microbiota. BMC Pregnancy Childbirth 21: 418.
16. Wang L, Yu KC, Hou YQ, Guo M, Yao F, et al. (2023) Gut microbiome in tumorigenesis and therapy of colorectal cancer. J Cell Physiol 238: 94-108.
17. Xu B, Qin W, Chen Y, Tang Y, Zhou S, et al. (2023) Multi-omics analysis reveals gut microbiota-ovary axis contributed to the follicular development difference between Meishan and Landrace × Yorkshire sows. Journal of Animal Science and Biotechnology 14: 68.
18. Wang J, Xu J, Han Q, Chu W, Lu G, et al. (2020) Changes in the vaginal microbiota associated with primary ovarian failure. BMC Microbiol 20: 230.
19. Kaur I, Suri V, Sachdeva N, Rana SV, Medhi B, et al. (2022) Efficacy of multi-strain probiotic along with dietary and lifestyle modifications on polycystic ovary syndrome: A randomised, double-blind placebo-controlled study. Eur J Nutr 61: 4145-4154.
20. Zhang J, Sun Z, Jiang S, Bai X, Ma C, et al. (2019) Probiotic Bifidobacterium lactis V9 Regulates the Secretion of Sex Hormones in Polycystic Ovary Syndrome Patients through the Gut-Brain Axis. mSystems 4: 00017-00019.
21. Oliver A, Chase AB, Weihe C, Orchanian SB, Riedel SF, et al. (2021) High-Fiber, Whole-Food Dietary Intervention Alters the Human Gut Microbiome but Not Fecal Short-Chain Fatty Acids. mSystems 6: 00115-00521.